Log in to your Inderes Free account to see all free content on this page.
Nanoform Finland
1.204
EUR
+0.67 %
3,515 following
NANOFH
First North Finland
Medical Equipment & Services
Health Care
Overview
Ownership
Investor consensus
+0.67%
-2.27%
-13.26%
-2.11%
-26.13%
-49.83%
-72.51%
-
-76.16%
Nanoform Finland is a medical technology company. The company specializes in the research and development of technical products used to create nanoparticles in pharmaceuticals. The technology is used as a complement in the production process and is used for the treatment of diseases such as ALS and Alzheimer's. The customers consist of companies in the global pharmaceutical industry. Nanoform Finland mainly operates in the Nordic market and is headquartered in Helsinki.
Read moreMarket cap
102.98M EUR
Turnover
12.45K EUR
Revenue
EBIT %
P/E
Dividend yield-%
Financial calendar
15.4.
2025
General meeting '25
20.5.
2025
Interim report Q1'25
21.8.
2025
Interim report Q2'25
All
Research
Webcasts
Press releases
ShowingAll content types

Nanoform, Audiocast with teleconference, Q4'24
Nanoform 2024 report: Deal discussions around product kernels intensify
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Invitation to Nanoform's Q4 and FY 2024 Report Presentation
Nanoform Finland Plc - Managers' transactions - Antonio Da Silva
Nanoform Finland Plc - Manager's Transactions - Peter Hänninen
Nanoform Finland Plc - Manager's Transactions - Edward Hæggström
Nanoform Finland Plc - Manager's Transactions - Albert Hæggström
The Board of Directors of Nanoform Finland Plc decided on issue of stock options under an option program open to all employees

Life Science Companies as Investments | Life Science Night Dec. 2, 2024
Nanoform Finland Plc - Manager's Transactions - Peter Hänninen
Nanoform Finland Plc - Manager's Transactions - Albert Hæggström

Nanoform, Audiocast with teleconference, Q3'24
Nanoform Q3 2024 report: Record number of new projects signed
Invitation to Nanoform's Q3 2024 Report Presentation
Disclosure as attachment of the Nanoform 2022 Report of the Board of Directors and Financial Statements which were previously linked to a Company Release
Share subscriptions based on Nanoform Finland Plc's stock options 2/2019
Nanoform and Celanese Expand Collaboration into Long-Acting Biologics Delivery Through Small Implants
